Pfizer to Acquire Array Biopharma for ~$11.4B

Pfizer to Acquire Array Biopharma for ~$11.4B

Shots:

  • Pfizer to acquire Array Biopharma in all-stock transaction for $48/share making the total deal value ~11.4B, with its expected completion in H2’19
  • The focus of the acquisition is to bolster Pfizer’s oncology portfolio with the addition of Array’s combined therapy of Braftovi (encorafenib) and Mektovi (binimetinib) indicated for the treatment of BRAFV600E or BRAFV600K mutant unresectable or metastatic melanoma
  • Braftovi and Mektovi are BRAF/MEK inhibitors, being evaluated in P-III BEACON study as a triple combination therapy (braftovi + mektovi + cetuximab) in patients with BRAF-mutant mCRC with its expected regulatory submission in the US in H2’19

Click here to read full press release/ article | Ref: Pfizer | Image: Leaderonomics